EMA has formalised its working relations with a number of third-country regulators through working arrangements.
These arrangements enable the parties to exchange information and provide a framework for regulatory cooperation. Their scope focusses on centrally authorised products, including marketing authorisation applications and referrals for human and veterinary medicines.
The emphasis is on exchange of information concerning regulatory guidance, legislation and non-public information on products, as well as safety information including adverse reactions, good manufacturing practice (GMP) and good clinical practice (GCP) inspection findings.
EMA has standing working arrangements with:
EMA can also establish ad-hoc working arrangements with international regulators to address specific public-health needs. These agreements have a limited scope and duration.
The EU has signed a number of mutual recognition agreements with third-country authorities concerning the conformity assessment of regulated products, which cover the mutual recognition of GMP compliance for human and veterinary medicines.
These agreements aim to facilitate market access while protecting consumer safety and encourage greater international harmonisation of compliance standards.
The EU has mutual recognition agreements with:
An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.
The tracking of updates begins in June 2026.
30 June 2026